Agenus (Nasdaq:AGEN) - Stock Price, News & Analysis

AGEN Stock Overview

A clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally.

About the company

AGEN fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Trading at good value compared to peers and industry

Risk Analysis

Negative shareholders equity

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 1.7% per year for the next 3 years

Highly volatile share price over the past 3 months compared to the US market

+ 3 more risks

Agenus Inc. Competitors

Assembly Biosciences

NasdaqGS:ASMB

US$93.4m

Coherus BioSciences

NasdaqGM:CHRS

US$123.3m

Elutia

NasdaqCM:ELUT

US$129.8m

Karyopharm Therapeutics

NasdaqGS:KPTI

US$108.5m

Price History & Performance

Summary of all time highs, changes and price drops for Agenus
Historical stock prices
Current Share Price	US$4.65
52 Week High	US$23.20
52 Week Low	US$4.41
Beta	1.36
11 Month Change	-9.36%
3 Month Change	-69.79%
1 Year Change	-78.27%
33 Year Change	-95.69%
5 Year Change	-91.06%
Change since IPO	-99.94%

Agenus: Novel Drugs That Just Are Not Novel

Jul 24

Recent updates

Agenus: Novel Drugs That Just Are Not Novel

Jul 24

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

May 21

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

May 09

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Mar 29

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Jan 18

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Dec 22

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Nov 09

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Oct 04

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

May 10

Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains

Aug 25

Agenus Multiple Value-Adding Events Ahead

Aug 18

Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

Aug 11

Shareholder Returns

	AGEN	US Biotechs	US Market
7D	-4.1%	-1.1%	0.6%
1Y	-78.3%	17.1%	30.3%

Return vs Industry: AGEN underperformed the US Biotechs industry which returned 17.1% over the past year.

Return vs Market: AGEN underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is AGEN's price volatile compared to industry and market?
AGEN volatility
AGEN Average Weekly Movement	20.8%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

Stable Share Price: AGEN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: AGEN's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1994	389	Garo Armen	www.agenusbio.com

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.

Agenus Inc. Fundamentals Summary

How do Agenus's earnings and revenue compare to its market cap?
AGEN fundamental statistics
Market cap	US$98.15m
Earnings (TTM)	-US$223.67m
Revenue (TTM)	US$159.63m

0.6x

P/S Ratio

-0.4x

P/E Ratio

Is AGEN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AGEN income statement (TTM)
Revenue	US$159.63m
Cost of Revenue	US$199.65m
Gross Profit	-US$40.02m
Other Expenses	US$183.65m
Earnings	-US$223.67m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-10.37
Gross Margin	-25.07%
Net Profit Margin	-140.12%
Debt/Equity Ratio	-6.1%

How did AGEN perform over the long term?

See historical performance and comparison

AGEN Stock Overview

Rewards

Risk Analysis

Agenus Inc. Competitors

NasdaqGS:ASMB

US$93.4m

NasdaqGM:CHRS

US$123.3m

NasdaqCM:ELUT

US$129.8m

NasdaqGS:KPTI

US$108.5m

Price History & Performance

Recent News & Updates

Rosen Law Firm Announces the Filing of a Class Action Lawsuit Against Agenus Inc

Agenus Inc. Appoints Tom Harrison to Its Board of Directors

Agenus Inc. to Report Q2, 2024 Results on Aug 08, 2024

Agenus: Novel Drugs That Just Are Not Novel

Agenus Inc. Announces End-Of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for Bot/Bal in MSS Colorectal Cancer

Agenus Inc Announces Results from an Investigator-Sponsored Trial (IST) of Botensilimab and Balstilimab (BOT/BALl) in the Neoadjuvant Setting for Colon Cancer

Recent updates

Rosen Law Firm Announces the Filing of a Class Action Lawsuit Against Agenus Inc

Agenus Inc. Appoints Tom Harrison to Its Board of Directors

Agenus Inc. to Report Q2, 2024 Results on Aug 08, 2024

Agenus: Novel Drugs That Just Are Not Novel

Agenus Inc. Announces End-Of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for Bot/Bal in MSS Colorectal Cancer

Agenus Inc Announces Results from an Investigator-Sponsored Trial (IST) of Botensilimab and Balstilimab (BOT/BALl) in the Neoadjuvant Setting for Colon Cancer

Agenus Inc. Announces Availability of Botensilimab for Clinical Studies

Agenus Appoints Jennifer Buell to Its Board of Directors

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer

Consensus revenue estimates fall by 27%

New major risk - Financial position

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus’ Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement

Agenus Inc., Annual General Meeting, Jun 11, 2024

Agenus Inc. to Report Q1, 2024 Results on May 07, 2024

New major risk - Share price stability

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Consensus revenue estimates increase by 30%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

Agenus Inc. to Report Q4, 2023 Results on Mar 14, 2024

Founder recently bought US$324k worth of stock

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 17% to US$6.67

Agenus Inc. to Report Q3, 2023 Results on Nov 07, 2023

Agenus Inc. Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

Agenus Inc. Announces Expanded Data from the Company's Phase 1B Study of Botensilimab in Combination with Balstilimab (Bal, Anti-Pd-1) in Patients with Advanced Sarcomas

Now 22% undervalued after recent price drop

Agenus Inc. Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Agenus Inc. Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Inc. to Report Q2, 2023 Results on Aug 08, 2023

Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Agenus Inc. Announces the Resignation of Wadih Jordan as Director, Effective December 31, 2022

Price target decreased to US$6.33

Insufficient new directors

Agenus Inc. Data At SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. to Report Q3, 2022 Results on Nov 08, 2022

Agenus Inc. Announces GSK Disclose Positive Pivotal Phase III Trial Results for Its Respiratory Syncytial Virus Vaccine Candidate

VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma

Investor sentiment improved over the past week

Price target decreased to US$6.33

Agenus New Trials Set It Up For The Long Haul